The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro

British Journal of Pharmacology

Volumn 166, Issue 8, 2012, Pages 2362-2370

  Ancrenaz, V ^a   Desmeules, J ^a,b   James, R ^a   Fontana, P ^a   Reny, J L ^a   Dayer, P ^a,b   Daali, Y ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

clopidogrel; cytochrome P450; metabolism; paraoxonase 1; polymorphism

Indexed keywords

2 OXO CLOPIDOGREL; ANTIBODY; ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A; DRUG METABOLITE; EDETIC ACID; ENZYME INHIBITOR; RECOMBINANT ARYLDIALKYLPHOSPHATASE 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTYPE; HUMAN; IN VITRO STUDY; LIVER MICROSOME; METABOLITE; PRIORITY JOURNAL; SERUM;

ANTIBODIES, MONOCLONAL; ARYLDIALKYLPHOSPHATASE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HUMANS; MICROSOMES; MICROSOMES, LIVER; MOLECULAR STRUCTURE; TANDEM MASS SPECTROMETRY; TICLOPIDINE;

EID: 84863482802     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01946.x     Document Type: Article

References (44)

1. Ancrenaz V, Daali Y, Fontana P, Besson M, Samer C, Dayer P, et al,. (2010). Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 11: 667-677.
2. Blatter Garin MC, Abbott C, Messmer S, Mackness M, Durrington P, Pometta D, et al,. (1994). Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 304: 549-554. (Pubitemid 24368237)
3. Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C, et al,. (2011). Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17: 110-116.
4. Clarke TA, Waskell LA, (2003). The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31: 53-59. (Pubitemid 36735258)
5. Combescure C, Fontana P, Mallouk N, Berdague P, Labruyere C, Barazer I, et al,. (2010). Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 8: 923-933.
6. Dansette PM, Rosi J, Bertho G, Mansuy D, (2011). Paraoxonase-1 and clopidogrel efficacy. Nat Med 17: 1040-1041. Author reply 1042-1044.
7. Deakin S, Guernier S, James RW, (2007). Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet Genomics 17: 451-457. (Pubitemid 46763390)
8. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS, (2009). Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53: 1273-1278.
9. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE, (2001). A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29: 23-29. (Pubitemid 32041675)
10. Eckerson HW, Wyte CM, La Du BN, (1983). The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35: 1126-1138. (Pubitemid 14201166)
11. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al,. (2007). Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81: 735-741. (Pubitemid 46625113)
12. Fontana P, Hulot JS, De Moerloose P, Gaussem P, (2007). Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 5: 2153-2155. (Pubitemid 47450038)
13. Fontana P, James R, Barazer I, Berdague P, Schved JF, Rebsamen M, et al,. (2011). Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 9: 1664-1666.
14. Ford NF, (2009). Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol 49: 506-512.
15. Gallemann D, Wimmer E, Hofer CC, Freisleben A, Fluck M, Ladstetter B, et al,. (2010). In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos 38: 905-916.
16. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al,. (2008). Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51: 256-260.
17. Gonzalvo MC, Gil F, Hernandez AF, Villanueva E, Pla A, (1997). Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 105: 169-179. (Pubitemid 27353307)
18. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM, (2003). Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2908-2913. (Pubitemid 36736631)
19. Gurbel PA, Antonino MJ, Tantry US, (2009). Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 5: 989-1004.
20. Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T, (2008). Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 23: 412-420.
21. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al,. (2006). Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244-2247. (Pubitemid 44497506)
22. Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, et al,. (2011). CYP2C19 but not PON1 Genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 4: 422-428.
23. Juurlink DN, (2009). Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 120: 2310-2312.
24. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al,. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38: 92-99.
25. Kolansky DM, Klugherz BD, Curran SC, Herrmann HC, Magness K, Wilensky RL, et al,. (2000). Combination therapy with clopidogrel and aspirin after coronary stenting. Catheter Cardiovasc Interv 50: 276-279. (Pubitemid 30439368)
26. Korhonen LE, Turpeinen M, Rahnasto M, Wittekindt C, Poso A, Pelkonen O, et al,. (2007). New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Br J Pharmacol 150: 932-942. (Pubitemid 46536632)
27. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al,. (2003). Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107: 32-37. (Pubitemid 36070929)
28. Lau WC, Carville DG, Bates ER, (2004a). Clinical significance of the atorvastatin-clopidogrel drug-drug interaction. Circulation 110: e66-e67. Author reply e66-e67.
29. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al,. (2004b). Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109: 166-171. (Pubitemid 38114134)
30. Mackness MI, Arrol S, Durrington PN, (1991). Substrate specificity of human serum paraoxonase. Biochem Soc Trans 19: 304S.
31. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al,. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354-362.
32. Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB, (2009). The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 19: 877-883.
33. Quinn MJ, Fitzgerald DJ, (1999). Ticlopidine and clopidogrel. Circulation 100: 1667-1672. (Pubitemid 29477278)
34. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, et al,. (1994). The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72: 313-317. (Pubitemid 24251300)
35. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al,. (2000). Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84: 891-896.
36. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP, (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423. (Pubitemid 24229655)
37. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al,. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302: 849-857.
38. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, et al,. (2009). Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101: 714-719.
39. Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, et al,. (2011). No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 32: 1605-1613.
40. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B, (2009). Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157: 148. e1-5.
41. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al,. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363-375.
42. Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN, (1991). Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Dispos 19: 107-112.
43. Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, et al,. (2011). Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 4: 429-436.
44. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J, (2004). Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363: 689-695. (Pubitemid 38296555)